MGT 1. 0: After successfully trialing Mascoma’s base strain Cream Yeast, Release 0 in at least one VRF plant, the next phase of the Agreement will commence when Mascoma receives Regulatory Approval for the first enzyme producing strain, MGT 1.0, and VRF has submitted a certification to the EPA for a Tier 1 exemption. The MGT 1.0 strain will produce sufficient glucoamylase to permit a significant reduction in exogenous enzyme usage, without negatively impacting ethanol yields, final ethanol titer or the time required for fermentation when compared to the current VRF plant operation. This period will involve demonstration of the MGT 1.0 yeast [***]. The intent of this phase is to validate the replacement of exogenous glucoamylase enzyme addition and existing commercial yeast with the Product . The plan is to initially trial by alternating [***] batches of MGT 1.0 followed by [***] batches of commercial yeast. At the start of the trial, it is likely that exogenous glucoamylase enzyme (GA) will still be added, and during the course of the trial the amount used will be gradually scaled back toward zero, commensurate with maintaining yield parity when compared to the preceding batches of commercial yeast. Once the reduction in GA addition achievable has been quantified, the plant would then transition to just running MGT 1.0. These trials with alternating yeasts will generate comparisons against existing performance achieved with conventional technology, and quantify the benefits that the use of MGT 1.0 provides and in doing so set the plants’ Royalty Fees.
MGT 1. 0: After successfully trialing Mascoma’s base strain Cream Yeast, Release 0 in at least one VRF plant, the next phase of the Agreement will commence when Mascoma receives Regulatory Approval for the first enzyme producing strain, MGT 1.0, and VRF has submitted a certification to the EPA for a Tier 1 exemption. The MGT 1.0 strain will produce sufficient glucoamylase to permit a significant reduction in exogenous enzyme usage, without negatively impacting ethanol yields, final ethanol titer or the time required for fermentation when compared to the current VRF plant operation. This period will involve demonstration of the MGT 1.0 yeast [***]. The intent of this phase is to validate the replacement of exogenous glucoamylase enzyme addition and existing commercial yeast with the Product. [***]
